Luminex Corporation Places 5,000th Instrument
21 February 2008 - 5:00AM
Business Wire
Luminex Corporation (NASDAQ: LMNX), the worldwide leader in
multiplexed solutions, today announced that it has recently
delivered its 5,000th instrument to Beaumont Hospital in Royal Oak,
Michigan. Beaumont Hospital, Royal Oak, will use the Luminex� 200�
instrument to perform the FDA-cleared Luminex xTAG� Respiratory
Viral Panel (RVP) to assist doctors in diagnosing respiratory
infections quickly. �Multiplexing is, in many ways, the future of
molecular diagnostics," said Dr. Domnita Crisan, medical director
of the molecular pathology laboratory at Beaumont Hospital, Royal
Oak. �The ability to run many tests at once provides us faster,
more clinically relevant results. The Luminex instrument is an
important multiplexing tool for us. It provides accurate results
very quickly and efficiently, and is easy to use.� The Luminex
analyzer is a unique instrument that can be used across the
continuum of science and healthcare � from basic research to
clinical diagnostics. The instrument can be found in pharmaceutical
and academic research laboratories, clinical reference laboratories
and hospitals of all sizes. �Delivering our 5,000th instrument is
an important milestone for Luminex as our proprietary xMAP�
Technology, driven by the test menu expansion of our partners and
the Luminex Assay Group, continues to gain momentum in the
marketplace,� said Patrick J. Balthrop, president and chief
executive officer of Luminex Corporation. �Our product portfolio
now includes a diversity of applications, such as the newly
launched xTAG RVP and FlexmiR� microRNA assays. These tests,
combined with our partners� developments in protein research,
immunodiagnostics, HLA and other areas, have led to record
instrument sales for Luminex. We look forward to working with our
partners and end-users to continue finding new ways our xMAP
Technology can advance science and healthcare.� Luminex instruments
are flexible analyzers based on the principles of three-dimensional
bead arrays. Due to the enhanced liquid kinetics of the
microspheres in solution, these arrays offer superior uniformity
and faster reaction times than standard two-dimensional planar
arrays. Proprietary xMAP Technology from Luminex also provides the
laboratory the power of multiplexing and the ability to produce
superior results in much less time than traditional methods like
ELISA or real-time PCR. Luminex develops and manufactures
state-of-the-art assay products, and licenses its instruments and
bead-based xMAP technology to market-leading companies in clinical
diagnostics and biological research. Assays from Luminex and its
partners deliver fast and cost-effective results for nucleic acid
assays, receptor-ligand assays, immunoassays and enzymatic assays.
About Luminex Corporation Luminex Corporation develops,
manufactures and markets proprietary biological testing
technologies with applications throughout the diagnostic and life
sciences industries. The Company's xMAP� multiplex solutions
include an open-architecture, multi-analyte technology platform
that delivers fast, accurate and cost-effective bioassay results to
markets as diverse as pharmaceutical drug discovery, clinical
diagnostics and biomedical research, including the genomics and
proteomics research markets. The Company's xMAP technology is sold
worldwide and is already in use in leading clinical laboratories as
well as major pharmaceutical, diagnostic and biotechnology
companies. Further information on Luminex Corporation or xMAP
technology can be obtained at www.luminexcorp.com.
Luminex (NASDAQ:LMNX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Luminex (NASDAQ:LMNX)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Luminex Corporation (NASDAQ): 0 recent articles
More Luminex Corporation News Articles